Published in J Clin Invest on October 01, 2008
The Role of the Muscle-nervous System Interface in Cancer Cachexia (NUMANCAN) | NCT03477721
Immunity, inflammation, and cancer. Cell (2010) 28.27
STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer (2009) 15.45
Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev (2009) 4.10
HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med (2010) 4.00
Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol (2010) 3.86
Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell (2009) 3.71
Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res (2009) 3.07
In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol (2009) 2.76
Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med (2012) 2.71
STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat Med (2010) 2.41
Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev (2009) 2.35
The NOD-like receptor NLRP12 attenuates colon inflammation and tumorigenesis. Cancer Cell (2011) 2.18
Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer (2010) 2.04
Essentials of Th17 cell commitment and plasticity. Blood (2013) 1.95
Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res (2010) 1.92
Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology (2012) 1.78
Development and function of myeloid-derived suppressor cells generated from mouse embryonic and hematopoietic stem cells. Stem Cells (2010) 1.75
Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling? Cell Div (2010) 1.70
Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target. Int J Biol Sci (2011) 1.70
S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. Cancer Cell (2012) 1.64
Contribution of MyD88 to the tumor exosome-mediated induction of myeloid derived suppressor cells. Am J Pathol (2010) 1.61
The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia (2013) 1.58
MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol (2011) 1.51
Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy. Cancer Res (2009) 1.46
IL-17 enhances tumor development in carcinogen-induced skin cancer. Cancer Res (2010) 1.45
CD5 Binds to Interleukin-6 and Induces a Feed-Forward Loop with the Transcription Factor STAT3 in B Cells to Promote Cancer. Immunity (2016) 1.44
CD8+ T-cell immunosurveillance constrains lymphoid premetastatic myeloid cell accumulation. Eur J Immunol (2014) 1.43
The metastasis-promoting roles of tumor-associated immune cells. J Mol Med (Berl) (2013) 1.40
Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. Cancer Res (2010) 1.34
Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis. J Immunol (2013) 1.34
Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. J Clin Invest (2013) 1.33
Role of endothelial progenitors and other bone marrow-derived cells in the development of the tumor vasculature. Angiogenesis (2009) 1.31
Dual roles for immunity in gastrointestinal cancers. J Clin Oncol (2010) 1.31
STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma. Cancer Res (2011) 1.30
Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu Rev Med (2014) 1.29
NF-κB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein Cell (2013) 1.25
Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment. Adv Cancer Res (2015) 1.25
Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. Cancer Res (2011) 1.23
Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLoS One (2013) 1.22
The cardioprotective protein apolipoprotein A1 promotes potent anti-tumorigenic effects. J Biol Chem (2013) 1.22
The impact of the immune system on tumor: angiogenesis and vascular remodeling. Front Oncol (2014) 1.22
STAT3: a target to enhance antitumor immune response. Curr Top Microbiol Immunol (2011) 1.18
Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells. Cancer Res (2010) 1.18
High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma. J Hematol Oncol (2011) 1.18
Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer. Front Oncol (2013) 1.17
Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention. Cancers (Basel) (2014) 1.17
TLR9 signaling in the tumor microenvironment initiates cancer recurrence after radiotherapy. Cancer Res (2013) 1.14
Targeting the tumor microenvironment: JAK-STAT3 signaling. JAKSTAT (2013) 1.14
Signaling pathways involved in MDSC regulation. Biochim Biophys Acta (2014) 1.12
Rho GTPases modulate malignant transformation of tumor cells. Small GTPases (2014) 1.12
The two faces of IL-6 in the tumor microenvironment. Semin Immunol (2014) 1.10
Host miR155 promotes tumor growth through a myeloid-derived suppressor cell-dependent mechanism. Cancer Res (2014) 1.06
STAT3 activation: A key factor in tumor immunoescape. JAKSTAT (2013) 1.04
STAT3 activation in monocytes accelerates liver cancer progression. BMC Cancer (2011) 1.04
Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma. Oncotarget (2012) 1.00
Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship. Immunol Invest (2012) 1.00
Myeloid-derived suppressor cells are involved in lysosomal acid lipase deficiency-induced endothelial cell dysfunctions. J Immunol (2014) 0.99
Induction of Bv8 expression by granulocyte colony-stimulating factor in CD11b+Gr1+ cells: key role of Stat3 signaling. J Biol Chem (2012) 0.98
Inhibition of Stat3 activation by sanguinarine suppresses prostate cancer cell growth and invasion. Prostate (2011) 0.97
Orchestration of angiogenesis by immune cells. Front Oncol (2014) 0.97
Immune cells and angiogenesis. J Cell Mol Med (2009) 0.96
Caveolin-1 upregulation mediates suppression of primary breast tumor growth and brain metastases by stat3 inhibition. Cancer Res (2011) 0.95
Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines. PLoS One (2012) 0.95
The Role of STAT3 in Non-Small Cell Lung Cancer. Cancers (Basel) (2014) 0.94
STAT3 in Cancer-Friend or Foe? Cancers (Basel) (2014) 0.93
Mechanisms driving macrophage diversity and specialization in distinct tumor microenvironments and parallelisms with other tissues. Front Immunol (2014) 0.92
The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer. Cancers (Basel) (2014) 0.91
Tumor angiogenesis mediated by myeloid cells is negatively regulated by CEACAM1. Cancer Res (2012) 0.91
B cells promote tumor progression via STAT3 regulated-angiogenesis. PLoS One (2013) 0.90
Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics. Cancer J (2013) 0.90
Transcriptional activation of hypoxia-inducible factor-1 (HIF-1) in myeloid cells promotes angiogenesis through VEGF and S100A8. Proc Natl Acad Sci U S A (2014) 0.90
Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication. Oncoimmunology (2015) 0.89
Prognostic significance of B-cells and pSTAT3 in patients with ovarian cancer. PLoS One (2013) 0.89
Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer. Cancer J (2013) 0.88
CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation. Immunity (2016) 0.88
STAT5 and prolactin participate in a positive autocrine feedback loop that promotes angiogenesis. J Biol Chem (2013) 0.87
The role of tumor-associated macrophages in tumor vascularization. Vasc Cell (2013) 0.87
Parathyroid hormone-related protein drives a CD11b+Gr1+ cell-mediated positive feedback loop to support prostate cancer growth. Cancer Res (2013) 0.87
Targeted STAT3 disruption in myeloid cells alters immunosuppressor cell abundance in a murine model of spontaneous medulloblastoma. J Leukoc Biol (2013) 0.86
MDSCs mediate angiogenesis and predispose canine mammary tumor cells for metastasis via IL-28/IL-28RA (IFN-λ) signaling. PLoS One (2014) 0.86
Myeloid clusters are associated with a pro-metastatic environment and poor prognosis in smoking-related early stage non-small cell lung cancer. PLoS One (2013) 0.86
Adenosine augments IL-10-induced STAT3 signaling in M2c macrophages. J Leukoc Biol (2013) 0.86
The therapeutic value of targeting inflammation in gastrointestinal cancers. Trends Pharmacol Sci (2014) 0.86
G-protein-coupled receptor agonist BV8/prokineticin-2 and STAT3 protein form a feed-forward loop in both normal and malignant myeloid cells. J Biol Chem (2013) 0.85
Intertwined regulation of angiogenesis and immunity by myeloid cells. Trends Immunol (2015) 0.84
Tolerance and immune suppression in the tumor microenvironment. Cell Immunol (2015) 0.84
Molecular pathways: myeloid complicity in cancer. Clin Cancer Res (2014) 0.84
Myeloid-derived suppressor cells modulate immune responses independently of NADPH oxidase in the ovarian tumor microenvironment in mice. PLoS One (2013) 0.83
STAT3 activation in tumor cell-free lymph nodes predicts a poor prognosis for gastric cancer. Int J Clin Exp Pathol (2014) 0.83
Myeloid-Derived Suppressor Cells and Therapeutic Strategies in Cancer. Mediators Inflamm (2015) 0.83
Evidence for a functional thymic stromal lymphopoietin signaling axis in fibrotic lung disease. J Immunol (2013) 0.83
Cancer and diet: How are they related? Free Radic Res (2011) 0.81
A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma. J Immunother Cancer (2014) 0.81
Targeting the adenosine A2b receptor in the tumor microenvironment overcomes local immunosuppression by myeloid-derived suppressor cells. Oncoimmunology (2014) 0.80
Increased circulating myeloid-derived suppressor cells correlate with cancer stages, interleukin-8 and -6 in prostate cancer. Int J Clin Exp Med (2014) 0.80
Reduction of myeloid-derived suppressor cells and lymphoma growth by a natural triterpenoid. J Cell Biochem (2015) 0.80
Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies. Oncotarget (2016) 0.80
Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy. Oncotarget (2016) 0.79
Density of Gr1-positive myeloid precursor cells, p-STAT3 expression and gene expression pattern in canine mammary cancer metastasis. Vet Res Commun (2011) 0.79
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer (2004) 14.55
Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell (2006) 13.79
The STATs of cancer--new molecular targets come of age. Nat Rev Cancer (2004) 13.07
Cancer and the chemokine network. Nat Rev Cancer (2004) 10.27
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol (2007) 9.37
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell (2004) 7.61
Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell (2008) 6.78
Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res (2007) 6.60
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med (2005) 6.58
Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest (2007) 6.31
Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science (1995) 6.28
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene (2002) 6.17
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med (2003) 5.96
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest (2007) 5.17
New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol (2005) 4.53
Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol (2006) 4.43
Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res (2007) 4.39
The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol (2007) 3.95
IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A (2003) 3.80
Does the immune system see tumors as foreign or self? Annu Rev Immunol (2001) 3.71
Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med (2005) 3.64
The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med (2006) 3.47
Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood (2003) 3.47
Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med (2005) 3.01
Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol (2005) 2.96
Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene (2003) 2.79
STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. Immunity (2002) 2.77
Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res (2006) 2.70
Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood (2007) 2.65
Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell (2005) 2.47
Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res (2007) 2.41
Tissue-specific microvascular endothelial cell lines from H-2K(b)-tsA58 mice for studies of angiogenesis and metastasis. Cancer Res (2003) 2.32
Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci U S A (2004) 2.25
Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth. J Clin Invest (2005) 2.20
STAT3 governs distinct pathways in emergency granulopoiesis and mature neutrophils. Blood (2006) 2.12
Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res (1999) 2.09
The contribution of bone marrow-derived cells to the tumor vasculature in neuroblastoma is matrix metalloproteinase-9 dependent. Cancer Res (2005) 1.84
Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-beta 1. J Exp Med (2006) 1.84
Nuclear translocation of phosphorylated STAT3 is essential for vascular endothelial growth factor-induced human dermal microvascular endothelial cell migration and tube formation. J Biol Chem (2003) 1.66
PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cell Signal (2007) 1.58
VEGF differentially activates STAT3 in microvascular endothelial cells. FASEB J (2003) 1.53
Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J Immunol (2005) 1.34
Tumor promotion by tumor-associated macrophages. Adv Exp Med Biol (2007) 1.31
Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1. Oncogene (1999) 1.24
Coordinated oncogenic transformation and inhibition of host immune responses by the PAX3-FKHR fusion oncoprotein. J Exp Med (2005) 1.06
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol (2007) 9.37
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med (2005) 6.58
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene (2002) 6.17
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med (2003) 5.96
IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med (2009) 5.05
Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell (2009) 4.56
The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell (2009) 4.47
Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol (2007) 4.29
Differential effects of PER2 phosphorylation: molecular basis for the human familial advanced sleep phase syndrome (FASPS). Genes Dev (2006) 3.78
Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell (2009) 3.71
Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res (2009) 3.07
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene (2005) 3.05
Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene (2002) 2.81
In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol (2009) 2.76
A critical role for Stat3 signaling in immune tolerance. Immunity (2003) 2.41
STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat Med (2010) 2.41
Vesicular glycolysis provides on-board energy for fast axonal transport. Cell (2013) 2.33
Diagnostic accuracy of magnetic resonance angiography for internal carotid artery disease: a systematic review and meta-analysis. Stroke (2008) 2.33
Lipidic pore formation by the concerted action of proapoptotic BAX and tBID. J Biol Chem (2004) 2.06
ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody. MAbs (2010) 2.03
Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs (2010) 2.01
Histone deacetylase 3 (HDAC3) activity is regulated by interaction with protein serine/threonine phosphatase 4. Genes Dev (2005) 1.94
Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev (2005) 1.93
Role of Stat3 in regulating p53 expression and function. Mol Cell Biol (2005) 1.91
Using peripheral blood mononuclear cells to determine a gene expression profile of acute ischemic stroke: a pilot investigation. Circulation (2005) 1.79
Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther (2004) 1.70
AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR. Mol Cell Biol (2003) 1.68
S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. Cancer Cell (2012) 1.64
Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment. Clin Cancer Res (2010) 1.64
The Fabrication of Nano-Particles in Aqueous Solution From Oxyfluoride Glass Ceramics by Thermal Induction and Corrosion Treatment. Nanoscale Res Lett (2008) 1.59
Role of Stat3 in suppressing anti-tumor immunity. Curr Opin Immunol (2008) 1.52
Deletion of IFNγ enhances hepatocarcinogenesis in FXR knockout mice. J Hepatol (2012) 1.51
Tracking down lipid flippases and their biological functions. J Cell Sci (2004) 1.49
Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy. Cancer Res (2009) 1.46
IL-17 enhances tumor development in carcinogen-induced skin cancer. Cancer Res (2010) 1.45
Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1alpha RNA expression in both tumor cells and tumor-associated myeloid cells. Mol Cancer Res (2008) 1.43
Cell entry of arginine-rich peptides is independent of endocytosis. J Biol Chem (2008) 1.41
Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene (2002) 1.38
Real time analysis of STAT3 nucleocytoplasmic shuttling. J Biol Chem (2003) 1.38
The potential of fluorescent and spin-labeled steroid analogs to mimic natural cholesterol. J Biol Chem (2003) 1.37
Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways. Mol Cancer Res (2010) 1.35
Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. Cancer Res (2010) 1.34
Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J Immunol (2005) 1.34
STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma. Cancer Res (2011) 1.30
TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo. Blood (2013) 1.27
Critical role of STAT3 in IL-6-mediated drug resistance in human neuroblastoma. Cancer Res (2013) 1.26
Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. Proc Natl Acad Sci U S A (2012) 1.26
Live-cell analysis of cell penetration ability and toxicity of oligo-arginines. J Pept Sci (2008) 1.25
Stat3 as a potential target for cancer immunotherapy. J Immunother (2007) 1.24
Characterization of cyclin L2, a novel cyclin with an arginine/serine-rich domain: phosphorylation by DYRK1A and colocalization with splicing factors. J Biol Chem (2003) 1.23
Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. Cancer Res (2011) 1.23
Characterization of the ternary mixture of sphingomyelin, POPC, and cholesterol: support for an inhomogeneous lipid distribution at high temperatures. Biophys J (2008) 1.23
L-arginine improves dystrophic phenotype in mdx mice. Neurobiol Dis (2005) 1.23
Function of prokaryotic and eukaryotic ABC proteins in lipid transport. Biochim Biophys Acta (2004) 1.21
Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice. Glia (2009) 1.21
A system-level investigation into the mechanisms of Chinese Traditional Medicine: Compound Danshen Formula for cardiovascular disease treatment. PLoS One (2012) 1.20
STAT3: a target to enhance antitumor immune response. Curr Top Microbiol Immunol (2011) 1.18
Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells. Cancer Res (2010) 1.18
Celastrus-derived celastrol suppresses autoimmune arthritis by modulating antigen-induced cellular and humoral effector responses. J Biol Chem (2011) 1.18
Retracted Molecular cloning and characterization of the human AKT1 promoter uncovers its up-regulation by the Src/Stat3 pathway. J Biol Chem (2005) 1.17
Transbilayer movement of phospholipids at the main phase transition of lipid membranes: implications for rapid flip-flop in biological membranes. Biophys J (2002) 1.17
Heterogeneity of AMPA receptor trafficking and molecular interactions revealed by superresolution analysis of live cell imaging. Proc Natl Acad Sci U S A (2012) 1.16
Asymmetric addition of ceramides but not dihydroceramides promotes transbilayer (flip-flop) lipid motion in membranes. Biophys J (2004) 1.15
StarD10, a START domain protein overexpressed in breast cancer, functions as a phospholipid transfer protein. J Biol Chem (2005) 1.15
TLR9 signaling in the tumor microenvironment initiates cancer recurrence after radiotherapy. Cancer Res (2013) 1.14
Rapid nonvesicular transport of sterol between the plasma membrane domains of polarized hepatic cells. J Biol Chem (2002) 1.14
How lipid flippases can modulate membrane structure. Biochim Biophys Acta (2008) 1.13
Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling. Cancer Res (2013) 1.13
The relevance of salt bridges for the stability of the influenza virus hemagglutinin. FASEB J (2007) 1.13